Torus Biosystems
Cambridge, US · Founded 2019 · Delaware corporation
Biotech
Founders & leadership
DY
David Yu ZhangDirector
PY
Peng YinDirector
SM
Shawn MarcellExecutive Officer, Director
BL
Ben LindenExecutive Officer
AW
Adam WiechhausDirector
Reported raises · per SEC filings
Form D private placements▶$25.2MraisedMay 2021 · 6 investors · BiotechnologyRule 506(b)
▶$25.2MraisedMay 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Yu ZhangDirector
- Peng YinDirector
- Shawn MarcellExecutive Officer, Director
- Ben LindenExecutive Officer
- Adam WiechhausDirector
- Offering amount
- $25.2M
- Amount sold
- $25.2M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$2.2MraisedMar 2021 · 4 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMar 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn MarcellExecutive Officer, Director
- Ben LindenExecutive Officer
- David Yu ZhangDirector
- Peng YinDirector
- Offering amount
- $3M
- Amount sold
- $2.2M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedFeb 2020 · 1 investors · BiotechnologyRule 506(b)
▶$1.5MraisedFeb 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chenyang Victor ShiDirector
- David Yu ZhangDirector
- Philip GardellaExecutive Officer
- Peng YinExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.